Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-039042
Filing Date
2025-04-25
Accepted
2025-04-25 08:02:51
Documents
22
Period of Report
2025-05-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm252365-4_def14a.htm   iXBRL DEF 14A 2662353
5 GRAPHIC bc_capvsnetincome-4c.jpg GRAPHIC 65397
6 GRAPHIC bc_capvstsr-4c.jpg GRAPHIC 67678
7 GRAPHIC bc_chiefexecutiveofficer-4c.jpg GRAPHIC 42606
8 GRAPHIC lc_performance-4c.jpg GRAPHIC 120214
9 GRAPHIC lg_adaptimmune-4c.jpg GRAPHIC 15728
10 GRAPHIC px_adaptimmune25pg01-bw.jpg GRAPHIC 463054
11 GRAPHIC px_adaptimmune25pg02-bw.jpg GRAPHIC 375677
  Complete submission text file 0001104659-25-039042.txt   6674588

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA adap-20241231.xsd EX-101.SCH 7520
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE adap-20241231_lab.xml EX-101.LAB 32544
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE adap-20241231_pre.xml EX-101.PRE 6683
24 EXTRACTED XBRL INSTANCE DOCUMENT tm252365-4_def14a_htm.xml XML 211587
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37368 | Film No.: 25870047
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)